April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

April 30, 2026

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

The ASCO Post

March 24, 2026

Adjuvant Pembrolizumab Plus Belzutifan May Provide a New Standard of Care for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

Based on results from the phase III KEYNOTE-564 study,1 adjuvant pembrolizumab is currently a standard of care for patients with clear cell renal cell carcinoma who have an increased risk of recurrenc...

The ASCO Post

January 06, 2026

A Novel Paradigm in Acute Kidney Injury: Congestive Nephropathy in RCC With IVC Thrombus

Researchers have proposed a new mechanism of acute kidney injury to account for patients with renal cell carcinoma (RCC) who have an inferior vena cava (IVC) tumor thrombus, according to findings pres...

The ASCO Post

November 05, 2025

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

Dana-Farber

February 26, 2025

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

Dana-Farber

March 15, 2021

The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC)

Kidney Cancer Research: Andrew Schmidt, MBBS presents a study that identifies a very favorable risk group in advanced kidney cancer patients treated with first-line therapy. ASCO #GU21 abstract 339.

Dana-Farber

March 15, 2021

Analysis of Plasma KIM-1 as a Biomarker for Recurrence Risk After Resection for Localized Renal Cell Carcinoma

Kidney cancer research: Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma, presented by Vincent Wenxin Xu, MD at ASCO #GU21 abstract 342

Dana-Farber

March 15, 2021

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21

Dana-Farber